MedTech Atlas
Back to medical device regulatory guideAll countries
Middle East & AfricaENPublic regulatory overview

Iran

Market Overview Market profile: Iran is an important medical device market in the Middle East. Public hospitals, specialty centers, and private providers all create demand. Highend...

Updated: 2026-05-04

You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.

Sign in / register for full country report
Reference approval strategy

FDA / CE / MDSAP / NMPA benefits for this market

These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.

US FDA

510(k) / De Novo / PMAModerate benefit

FDA evidence is useful technical and clinical support, but the local authority still performs an independent review.

Likely benefit
  • Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
  • May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
  • Does not remove local holder, language, labeling, fee, import, or post-market obligations.
View topic

EU CE

MDR / IVDRModerate benefit

CE evidence provides a strong technical-file template but does not replace the local review.

Likely benefit
  • Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
  • Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
  • Does not replace local registration or local representative responsibilities outside the CE-recognized route.
View topic

MDSAP

Single QMS auditIndirect QMS signal

MDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.

Likely benefit
  • Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
  • Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
  • Does not authorize product sale and does not replace safety, performance, or clinical evidence.
View topic

China NMPA

China registration / filingSupportive evidence

NMPA approval can serve as prior-market evidence and a commercial credibility signal, especially for China-made products.

Likely benefit
  • Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
  • Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
  • Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
View topic

AI Citation Summary

  • Country: Iran
  • Product line: Medical devices
  • Regulator / source: Regulatory environment: Medical devices are generally handled within the Iran Food and Drug Administration (IFDA) / Food and Drug Organization (FDO) system under the Ministry of Health and Medical Education (MOHME). In practice, market-entry projects commonly encounter the Medical Equipment Department / IMED, Iran Registration Code (IRC), import permits, local authorised representatives, and Persian labeling.
  • Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
  • Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
  • Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
  • Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
  • Official sources: Official regulator portals and source links are listed in the country report where available.
  • Last verified: 2026-05-04
  • Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
  • Preferred citation: MedTech Atlas

Market Overview

  • Market profile: Iran is an important medical device market in the Middle East. Public hospitals, specialty centers, and private providers all create demand. High-end equipment, implants, IVDs, consumables, dialysis products, imaging systems, and surgical devices remain import-dependent, while basic consumables and some conventional devices have local manufacturing alternatives.
  • Regulatory environment: Medical devices are generally handled within the Iran Food and Drug Administration (IFDA) / Food and Drug Organization (FDO) system under the Ministry of Health and Medical Education (MOHME). In practice, market-entry projects commonly encounter the Medical Equipment Department / IMED, Iran Registration Code (IRC), import permits, local authorised representatives, and Persian labeling.
  • Core decision: Iran medical device entry is not only a product-registration question. A supplier must assess sanctions and export-control feasibility, the local authorised representative, control over registration and IRC, import clearance, hospital-channel access, after-sales service, payment, and end-user compliance together.

Regulatory Authority

...